| Issue Date | Title | Author(s) |
| 1-Jul-2019 | Effect of the PCSK9 inhibitor evolocumab on total cardiovascular events in patients with cardiovascular disease: A prespecified analysis from the FOURIER Trial | Murphy, SA; Pedersen, TR; Gaciong, ZA; Ceska, R; Ezhov, MV, et al |
| 6-Jan-2024 | Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study | Dharmayat, KI; Vallejo-Vaz, AJ; Stevens, CAT; Brandts, JM; Lyons, ARM, et al |
| 19-Mar-2019 | Lipoprotein(a), PCSK9 inhibition and cardiovascular risk: Insights from the FOURIER trial | O'Donoghue, ML; Fazio, S; Giugliano, RP; Stroes, ESG; Kanevsky, E, et al |
| 7-Dec-2016 | Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration | Vallejo-Vaz, A; Akram,, A; Seshasai,, R; Cole,, D; Watts, GF, et al |
| 31-Mar-2015 | Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel | Banach, M; Rizzo, M; Toth, PP; Farnier, M; Davidson, MH, et al |
| 4-Jun-2019 | The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: Conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation | Fruchart, J-C; Santos, RD; Aguilar-Salinas, C; Aikawa, M; Al Rasadi, K, et al |